半乳糖凝集素8(GAL8)活性蛋白
Active Galectin 8 (GAL8)
LGALS8; PCTA1; Po66-CBP; Prostate Carcinoma Tumor Antigen 1; Lectin,Galactoside-Binding Soluble 8; Po66 carbohydrate-binding protein; Prostate carcinoma tumor antigen 1
- 編號(hào)APA308Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)8.3
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1814 ¥ 4536 ¥ 9072 ¥ 27216 ¥ 68040
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
Galectin 8 (GAL8), also known as prostate carcinoma tumor antigen 1 (PCTA1) in human, is a tandem repeat-type galectin. is a member of the lectin family, of which 14 mammalian galectins have been identified. It is also a member of the beta-galactoside-binding protein family that plays an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis, apoptosis. In this case, we chose rabbit erythrocyte (RaE) to assay its ability of agglutination. A general procedure for hemagglutination assay (or haemagglutination assay; HA) is as follows, two-fold dilute the recombinant human GAL8 with 0.9% sodium chloride injection, add 50μL a serial dilution of GAL8 to each well of a U or V-bottom shaped 96-well microtiter plate. The final well serves as a negative control with no GAL8, replace with 50μL 0.9% sodium chloride injection. Then add 50μL 1% rabbit erythrocyte to each well and mixed gently. The plate is incubated for 3 hours at room temperature. The results are shown in Figure 1. It was obvious that the minimal effective concentration of GAL8 is 6.25μg/mL.
Figure 2. The hemagglutination assay of GAL8 in V- bottom shaped 96-well microtiter plate.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA308Hu01 | 半乳糖凝集素8(GAL8)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA308Hu01 | 半乳糖凝集素8(GAL8)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA308Hu01 | 半乳糖凝集素8(GAL8)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA308Hu71 | 半乳糖凝集素8(GAL8)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAA308Hu81 | 半乳糖凝集素8(GAL8)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| MAA308Hu27 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA308Hu25 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA308Hu24 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; ICC/IF |
| MAA308Hu29 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA308Hu23 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA308Hu21 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA308Hu22 | 半乳糖凝集素8(GAL8)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA308Hu | 半乳糖凝集素8(GAL8)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA308Hu | 半乳糖凝集素8(GAL8)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA308Hu01 | 半乳糖凝集素8(GAL8)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cell Metabolism | Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer [Pubmed: 31447322] |
| CALCIFIED TISSUE INTERNATIONAL | The Dysregulated Galectin Network Activates NF-κB to Induce Disease Markers and Matrix Degeneration in 3D Pellet Cultures of Osteoarthritic Chondrocytes [Pubmed: 33185768] |
